Approximately 50–60% of sepsis episodes are initially diagnosed in the emergency department (ED)1 with an estimated 3.9 million US patients presenting in the ED related to bloodstream infections (BSI).2 If BSI patients are appropriately treated in the ED, the risk of unplanned and urgent rehospitalization significantly decreases with timely and appropriate antibiotic treatment.3
According to ACEP DART* guidelines, it is recommended to administer appropriate antibiotics early – ideally within the first hour of recognition since delays can increase mortality rates.4 Inappropriate antibiotic therapy can lead to readmissions, which are 2 to 3 times more likely and more costly than readmits for heart failure, pneumonia, and COPD.5
While blood cultures are ordered as a part of the hospital’s sepsis alert bundle, results aren’t clinically actionable without the species ID or more. In a recent retrospective analysis of 13 U.S. hospitals and over 150,000 blood cultures, investigators reported that the median time to blood culture positivity and species identification was 43 hours6 – which is not fast enough to help guide physicians in early and appropriate antibiotic therapy for patients admitted into the hospital ED.6
Rapid diagnostic test results for patients presenting in the ED can enable physicians to better manage and treat patients faster.
T2Direct Diagnostics is the first and only FDA-cleared system to identify deadly sepsis-causing pathogens directly from whole blood without the need for blood culture. The T2Bacteria® Panel delivers faster, easier, and more accurate test results in 3 to 5 hours. The addition of T2Bacteria to a hospital’s SEP-1 bundle can get patients on the right treatment earlier and have a positive impact on patient care.
How rapid identification of a bacterial bloodstream infection fits into an emergency department sepsis protocol. ~ Dr. Frank Peacock, Professor of Emergency Medicine, Associate Chair, Research Director for the Department of Emergency Medicine at Baylor College of Medicine.
In the T2Bacteria pivotal clinical trial conducted in 11 U.S. centers with 1,427 patients, investigators demonstrated positive and highly accurate results 2.5 days faster and without the antimicrobial interference that can affect blood culture results.6
Contact us to request a demo of the T2Bacteria Panel!
……………………………………….
1. Garnacho-Montero J, et al. Critical Care, 2015
2. National Hospital Ambulatory Medical Care Survey: 2011 Emergency Department Summary Tables
3. Chan, J. et al. Canadian Journal of Emergency Medicine, 2015
4. American College of Emergency Physicians, DART Guidelines, 2018
5. Mayr FB, et al. JAMA, 2017
6. Tabak YP, et al. Journal of Clinical Microbiology, 2008
7. T2Bacteria Pivotal Clinical Study 2018. Manuscript under review.
8. Voigt C, et al. Manuscript in preparation, 2018
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Resistance® and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Lyme™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2024 T2 Biosystems, Inc.
Please tell us where you are visiting from: United States | Outside the United States
